CMS Issues Proposed Rule to Cover ‘Breakthrough’ Medical Devices

News
Published on:
August 11, 2020

The Centers for Medicare & Medicaid Services (CMS) issued a proposed rule this week that would give breakthrough medical devices national Medicare coverage on the same day they receive FDA approval for four years. The proposed rule, called Medicare Coverage of Innovative Technology (MCIT), would establish a Medicare coverage pathway that provides beneficiaries nationwide with faster access to new, innovative medical devices designated as ‘breakthrough’ by the Food and Drug Administration (FDA).

During the four year timeframe, CMS recommends that manufacturers develop additional evidence showing the applicability of their products to Medicare beneficiaries so they can apply for further coverage.

Before the MCIT, after a breakthrough technology receives FDA approval, an often lengthy and costly process for Medicare coverage begins. That period has been challenging for companies because innovators spent time and resources to achieve FDA approval, only to need to spend more time and money to acquire Medicare coverage. This lag time is not only costly but has also reduced access to innovative technologies by senior populations.

This proposed rule follows up on creating a pathway to Medicare coverage the same day as FDA market authorization for breakthrough devices. The proposal will be live from September 1, 2020 and open for comment till October 30, 2020. Additionally, the proposed rule would allow Medicare to cover eligible breakthrough devices the FDA has approved for use in 2019 or 2020.

What does it mean for you?

Organizations will need to understand the details of the breakthrough designation and how it applies to their innovation before proceeding. Moreover, what evidence needs to be generated in these four years to maintain coverage. The Alira Health team can help you understand how this designation applies to you, and how you can best leverage the proposed rule for your innovation.

For more information, please contact Deepak Sahu.

Click here to see the proposed rule from The Department of Health and Human Services.

Related news

Publications June 23, 2022
Developing Data Specialist Talent: Collaboration Is Key
Companies across Pharma and MedTech need talented people to cover the range of data-related challenges. Discover what this means for developing talent throughout the industry.
Data Specialist MedTech Pharma
Multimedia June 21, 2022
Increasing Access to Genomic Testing in Europe
Listen to the episode “Increasing Access to Genomic Testing in Europe: The role of national genomic initiatives in increasing uptake of Advanced Diagnostics”.
Genomic Testing Market Access MedTech
Publications May 27, 2022
The Impact of Chip Shortage on the MedTech Sector and RAS Players
Discover the three factors driving the chip shortage, the impact, and what’s next for Robotic and MedTech industry at large.
CDMO MedTech Robotcs
Events May 19, 2022
DIA 2022 Global Annual Meeting
We are pleased to announce that we will be joining DIA 2022 Global Annual Meeting as exhibitors and delegates.
Biometrics Clinical Life Sciences Regulatory
News May 11, 2022
Alira Health Acquires RedCrow, an Equity Crowdfunding Platform for Healthcare Startups
We acquired RedCrow, an alternative investment platform that provides individual investors with easy access to expert-vetted healthcare start-ups. The financial terms of the transaction(...)
MedTech Patient Engagement Pharma
Events May 9, 2022
7e Journée start-up innovantes du dispositif médical
Clinical Digital Health Market Access MedTech Research & Development
Uncategorized May 6, 2022
U.S. and European Clinical Development for Asian MedTech Startups
This webinar will focus on the U.S. FDA and EU MDR/IVDR regulatory pathways and strategies for medical device startups based in the Asia Pacific.
Clinical MedTech
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.